Mechanism walk-through, evidence map, dosing matrix, FAQ, and honest verdict. ~3,000 words grounded in 2026 clinical data.
CJC-1295 is a long-acting synthetic analog of endogenous growth hormone-releasing hormone (GHRH). It exists in two forms: CJC-1295 without DAC (sometimes called "Modified GRF 1–29") — a 29-amino-acid GHRH fragment with four amino-acid substitutions that improve plasma stability — and CJC-1295 with DAC (Drug Affinity Complex), which adds a lysine-based linker that covalently binds circulating albumin and dramatically extends the half-life from minutes to days. Both act at the same GHRH receptor on pituitary somatotrophs as Sermorelin, but with a longer pharmacokinetic window.
The peptide was originally investigated as a research tool for characterising the GHRH-receptor pathway and for studying sustained GH axis stimulation. It has never been FDA-approved for any indication. What is sold today as "CJC-1295" is exclusively the compounded gray-market or research-chemical product.
Two distinct conversations about CJC-1295 have collided online. They have very different evidence bases:
The extended half-life is a pharmacokinetic property, not a clinical superiority claim. Half-life extension at the same receptor step does not translate to additional efficacy evidence — it changes dosing frequency and exposure profile, not the weight of evidence for clinical outcomes.
CJC-1295's proposed mechanism is well-defined at the receptor-pharmacology level. Five distinct pathways are commonly cited, each with its own published trail. The DAC modification is the primary differentiator from Sermorelin; the receptor pharmacology is otherwise identical.
The foundational mechanism. CJC-1295 binds the GHRH receptor on pituitary somatotrophs and amplifies pulsatile GH release — the same receptor step as Sermorelin (GHRH 1–29) and endogenous GHRH. The four amino-acid substitutions in CJC-1295 (relative to native GHRH 1–29) improve plasma stability by reducing dipeptidyl-peptidase IV (DPP-IV) cleavage, extending the intrinsic half-life before albumin binding. The GHRH-receptor pharmacology is well-mapped and continuous with the 1990s GHRH-analog literature.
The Drug Affinity Complex modification is a maleimidoproprionic acid (MPA) linker that covalently binds the free thiol group on circulating albumin. Because albumin has an extremely long circulating half-life (>19 days), any peptide covalently bound to it acquires a dramatically extended exposure window. CJC-1295 with DAC has a reported terminal half-life of 6–8 days in the published pharmacokinetic literature — contrasted with Sermorelin's minutes and CJC-1295 without DAC's hours. This pharmacokinetic class difference is mechanistically real. It does not generate clinical efficacy data that does not exist for the non-DAC forms of GHRH-analog administration.
Like Sermorelin, CJC-1295 acts upstream through the pituitary GHRH-receptor pathway, and the resulting GH release retains pulsatile architecture — the upregulation of an endogenous step rather than a sustained supraphysiological plateau. However, the DAC modification's extended albumin-binding exposure creates a sustained baseline agonist stimulus that differs from the pulse-then-trough profile of short-acting GHRH analogs. Whether the DAC form truly preserves pulsatility at chronic community doses or blunts it through sustained receptor occupancy is not characterized in published human chronic-dose data.
The same synergy rationale that applies to Sermorelin + Ipamorelin applies to CJC-1295 + Ipamorelin. CJC-1295 acts at the GHRH receptor (upstream); GHRPs act at the GHS-R1a ghrelin receptor (downstream). Combined exposure produces supra-additive acute GH-pulse amplitude. The "CJC-1295 + Ipamorelin blend vial" is the most common commercial compounded form, specifically because the twice-weekly CJC-1295 (DAC form) pharmacokinetic window is aligned with the nightly Ipamorelin pulse schedule. The synergy is documented for acute GH-pulse amplitude; it has not been tested for any chronic clinical outcome in humans.
The pathway most invoked online, and the least supported by human evidence. GHRH-receptor activation is theoretically upstream of increased pulsatile GH — which is theoretically upstream of IGF-1-driven muscle protein synthesis, lipolysis, slow-wave sleep architecture, and connective-tissue maintenance. Those downstream effects are mechanistically expected if the upstream GH axis is amplified and sustained. They are not clinically demonstrated in any human RCT for adult body-composition, anti-aging, sleep quality, or recovery outcomes as of August 2026. The extended half-life of the DAC form does not close this evidence gap — longer exposure to an upstream mechanism class is not the same as evidence that the downstream clinical outcomes occur.
Mechanism vs. efficacy: CJC-1295 has a well-defined GHRH-receptor mechanism and a real pharmacokinetic class difference (DAC albumin-binding extends the half-life to days). These are pharmacological facts. They are not evidence of clinical efficacy for adult body-composition, anti-aging, or sleep-quality outcomes. Mechanisms justify investigation. Half-life extension justifies a different dosing schedule. Neither translates to proven clinical outcomes in healthy adults.
The table below ranks the strength of available evidence by indication for CJC-1295. Tier labels reuse the convention applied across the site: high for conditions supported by multiple human RCTs, med for supportive controlled human or limited human data, low and none for theoretical and absent categories.
| Indication | Evidence Tier | Best Study / Citation |
|---|---|---|
| GH-stimulation testing in adults (narrow-window diagnostic stim, GHRH-receptor class) | Strong controlled human (GHRH-class data) | Reutens 1996 single-administration adult pharmacodynamic study — acute GHRH-receptor amplification profile in healthy adults. PMID: 8834260. Evidence applies to the receptor class; CJC-1295-specific chronic-dose human stim data is absent. |
| GH-stimulation pharmacodynamic characterisation (GHRH-class, historical) | Controlled human (historical, GHRH-class) | Walker 1994 dataset anchoring the 1–29 GHRH-analog GH-stimulation-test literature in pediatric and adult subjects. PMID: 7527273. Same receptor class as CJC-1295; CJC-1295-specific pharmacokinetic data is not published at community doses. |
| Adult body composition / fat loss / lean-mass gain | No human RCT | No published human RCT demonstrates body-composition, fat-loss, or lean-mass outcomes from CJC-1295 (with or without DAC) as of August 2026. Community protocols extrapolate from GHRH-class single-dose data. |
| Anti-aging / longevity outcomes | Vendor-driven only | No published peer-reviewed human evidence supports anti-aging or longevity outcomes from CJC-1295. The DAC half-life extension does not generate outcome evidence that does not exist. |
| Sleep architecture / slow-wave sleep enhancement | Healthy-volunteer coupled-pulse only (GH class) | GH-pulse coupling with slow-wave sleep is well-characterised for the GH axis in healthy-volunteer overnight studies; no published RCT for chronic sleep complaints or sleep-quality outcomes from CJC-1295 specifically. |
| Adult-onset GH-deficiency (AGHD) therapy | Never approved for AGHD | CJC-1295 was never approved for adult GH-deficiency therapy. Recombinant GH (somatropin) is the FDA-approved AGHD therapy. Macimorelin is the oral GHS for AGHD diagnosis only. CJC-1295 has no regulatory approval for any indication. |
| Recovery from training / muscle repair | Extrapolated from GH axis | Animal data shows GH-axis modulation effects on muscle; human RCTs for training recovery from CJC-1295 do not exist. |
The GHRH-class pharmacodynamic data is genuine and reproducible: Reutens 1996 (PMID: 8834260) and Walker 1994 (PMID: 7527273) anchor a defined GHRH-receptor mechanism under controlled conditions. Both studies used short-acting GHRH analogs in single-dose diagnostic settings; CJC-1295-specific (especially DAC-form) chronic-dose human pharmacokinetics are not published. The body-composition and anti-aging evidence is absent for the CJC-1295 form specifically and for the GHRH-receptor class broadly in healthy-adult chronic-use contexts.
WADA's 2026 Prohibited List explicitly names CJC-1295 under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics — GH-Releasing Factors subcategory), in-competition and out-of-competition. FDA's July 2026 Compounding Docket reclassification review covers the GHRH-analog class including CJC-1295.
The gap between published research and online community content is largest in the dosing section. What follows compares what the GHRH-class published research actually used against what the gym-forum and peptide-clinic protocols typically recommend for CJC-1295 specifically.
| Source | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Walker 1994 / GHRH-class adult diagnostic-stimulation (GHRH 1–29 receptor class) | 1 mcg/kg | IV (single dose) | Single administration | GHRH-receptor class pharmacodynamic study — acute GHRH-receptor stimulation and serum GH response characterisation. PMID: 7527273. CJC-1295 was not used in this study. |
| Reutens 1996 / GHRH-class adult single-dose pharmacodynamic study | 1–2 mcg/kg | IV or SC (single dose) | Single administration | Acute GHRH-receptor amplification and pulsatile GH-release profile in healthy adults. PMID: 8834260. Short-acting GHRH 1–29 form; not the CJC-1295 DAC form studied at chronic dosing. |
| Community protocol: CJC-1295 without DAC (Modified GRF 1–29) | 100–300 mcg | Subcutaneous | 1–3x daily (typically pre-workout, before bed) | Anecdotal. No published human RCT validates any specific dose, schedule, or chronic-exposure profile for CJC-1295 without DAC at these protocols. |
| Community protocol: CJC-1295 with DAC | 1–2 mg | Subcutaneous | 1–2x weekly (extended half-life allows less frequent dosing) | Anecdotal. The albumin-binding DAC modification extends half-life to 6–8 days in animal models; published human chronic-dose PK at these community doses does not exist. |
| Community protocol: CJC-1295 + Ipamorelin blend vial | CJC-1295 (DAC) 1 mg + Ipamorelin 1 mg | Subcutaneous | 2x weekly (CJC-1295 window aligned with Ipamorelin nightly pulses) | The most common commercial blend format. The GHRH + GHRP synergy rationale is mechanistic (receptor-pathway complementarity); chronic outcome data in humans does not exist for this combination. |
| Human chronic-dose PK study (CJC-1295 specific) | None published | — | — | No published chronic-dose human PK, tolerability, or safety study of CJC-1295 (with or without DAC) at any community protocol dose as of August 2026. |
Why the DAC half-life extension does not resolve the evidence gap: CJC-1295 with DAC has a pharmacokinetically longer exposure window than Sermorelin or CJC-1295 without DAC — this is a documented pharmacokinetic property. A longer half-life changes dosing frequency and receptor occupancy profile; it does not substitute for published human efficacy data. Community protocols citing the DAC half-life as evidence of superiority are conflating a pharmacokinetic class with a clinical evidence class. The evidence gap for chronic adult body-composition, anti-aging, and recovery outcomes is identical to Sermorelin — the DAC form simply has not been studied either.
The GHRH-class anchor at single doses is real. The chronic-exposure evidence is not. Community protocols that cite Reutens 1996 / Walker 1994 as their evidence anchor are citing single-dose GHRH-class studies conducted with short-acting GHRH analogs under diagnostic conditions — the gap between that data and chronic weekly CJC-1295 (DAC) community protocols remains untested.
The list below is what promotional CJC-1295 content systematically omits.
The acute GHRH-receptor amplification data is sound for the class, but no published chronic-dose human safety study exists for CJC-1295 (with or without DAC) at any community protocol dose. Tolerability at twice-weekly subcutaneous administration for months (the typical community pattern with DAC) is unmeasured. IGF-1 drift over months of sustained albumin-bound exposure is unmeasured. Any claim of "I used CJC-1295 for 12 weeks with no issues" lacks the controlled bloodwork follow-up that would constitute evidence.
The DAC modification that makes CJC-1295 long-acting is itself uncharacterised in human chronic-dose contexts. Albumin binding and the resulting extended GHRH-receptor exposure window are pharmacologically real. The downstream safety profile of sustained (rather than pulsatile) GHRH-receptor agonism over weeks-to-months is not studied in humans. Whether sustained receptor occupancy at the GHRH step produces meaningful receptor downregulation, blunted endogenous GHRH tone, or disrupted pulsatility architecture is an open question — not a resolved one in any direction.
The pituitary GHRH receptor responds in a pulsatile fashion to endogenous stimulus; sustained agonist exposure theoretically produces receptor downregulation. The DAC form's extended half-life creates a sustained baseline agonist stimulus that differs from the pulse-then-trough profile of endogenous GHRH or short-acting GHRH analogs. Whether CJC-1295 with DAC at community protocols produces meaningful receptor downregulation is not measured in humans. The desensitization risk is specifically higher for the long-acting DAC form than for Sermorelin at physiologically-spaced nightly doses.
Sustained supra-physiological GH exposure (which CJC-1295 DAC chronic community protocols may produce) has documented glucose-homeostasis effects in the recombinant GH literature — insulin resistance, glucose intolerance, lipolysis-driven triglyceride shifts are real concerns at sustained GH elevations. Whether CJC-1295's long-acting GHRH-receptor agonism produces the same sustained GH profile as recombinant GH — and thus the same glucose-homeostasis risk — is not characterized at community chronic-dose levels.
There is no published reproductive toxicology data in any species for chronic CJC-1295 exposure. The GH/IGF-1 axis intersects with developmental biology; the safety profile in pregnancy or in women trying to conceive is unstudied. The compound should be considered as having an unknown teratogenicity profile.
No pharmacology study has systematically evaluated CJC-1295's interactions with somatostatin analogs, dopamine antagonists, anticholinergics, hormonal contraceptives, glucose-lowering agents, or any other common drug class. Users on any of these are using CJC-1295 off a complete pharmacology map.
CJC-1295 (with DAC in particular) requires more complex synthesis than shorter peptides. Without independent Certificate of Analysis (COA) showing identity, purity (>95%), and endotoxin testing from an accredited laboratory, there is no basis for assuming the compound purchased matches its label in dose, purity, or even molecular structure. The DAC linker chemistry is a specific synthetic step that is not trivial to verify without mass-spectrometry confirmation.
CJC-1295 is not an FDA-approved drug for any indication, in either the DAC or non-DAC form. Unlike Sermorelin (which had a narrow historical pediatric FDA approval before its 2008 commercial withdrawal), CJC-1295 has never reached an NDA or BLA submission in the US. It is a research chemical whose clinical development did not advance beyond early pharmacokinetic characterisation. There is no compounded monograph, no 503A/503B compounding envelope, and no established USP standard for CJC-1295; the product sits outside the FDA-approved pharmacy framework in a regulatory gray zone.
Because there is no current FDA-approved drug product and no established USP monograph for CJC-1295, compounding it for clinical use sits in a tenuous regulatory position — arguably more tenuous than Sermorelin, which at least had a withdrawn approval. The July 2026 FDA compounding reclassification review covers the GHRH-analog class including CJC-1295. If the class is moved to the restricted bulk-substance list, access through 503A/503B pharmacies may be sharply limited. The telehealth-clinic compounding market for CJC-1295 (typically combined with Ipamorelin in blend vials) is one of the primary use-case contexts driving this regulatory attention.
CJC-1295 is explicitly listed under WADA's S2 category — Peptide Hormones, Growth Factors, Related Substances and Mimetics — specifically under the "GH-Releasing Factors (GHRFs)" subcategory alongside Sermorelin, GHRP-2, GHRP-6, hexarelin, and the related analogs. This prohibition applies both in-competition and out-of-competition for all athletes subject to WADA testing. A positive test constitutes a full WADA anti-doping rule violation regardless of source, dose, or therapeutic rationale. The WADA listing covers both the DAC and non-DAC forms.
CJC-1295 sits in the same GH-Releasing Factors subcategory of S2 as Sermorelin, distinct from the GH-Releasing Peptides (GHRPs) subcategory that covers Ipamorelin and the older GHRPs. The two subcategories share the same S2 blanket prohibition; the receptor pathway is different but the practical athletic consequence is identical.
What this means practically: CJC-1295 purchased outside any FDA-approved channel is an unregulated compound. There is no manufacturer accountability and no guarantee of purity, identity, or dosing accuracy without independent lab testing. The regulatory environment is active — the 503A compounding conversation and WADA listing were both relevant in 2026.
CJC-1295's regulatory framing changes month to month — GHRH-class compounding eligibility, WADA S2 list updates, and the broader peptide-clinic enforcement environment all matter. The dated Regulatory Updates Log tracks the primary-source documents as they're published.
View CJC-1295 regulatory entries →CJC-1295 sits squarely in the GH-axis cluster alongside Sermorelin, Ipamorelin, and the broader GHRP / GHRF ecosystem. The most relevant comparisons are within that cluster and against the FDA-approved GH-axis options.
Same upstream GHRH receptor. Different pharmacokinetic half-life class. Sermorelin (GHRH 1–29, short-acting, minutes) vs CJC-1295 with DAC (albumin-binding modification, days). The community framing of "weekly CJC-1295 instead of nightly Sermorelin" is a dosing-frequency consequence of the half-life difference, not a clinical superiority claim. Both peptides share the same evidence base (Reutens 1996, Walker 1994 GHRH-class data), the same zero-body-composition-RCT profile, the same WADA S2 / GH-Releasing Factors subcategory prohibition, and the same chronic-dose safety gaps. Half-life is not a substitute for efficacy evidence.
Full comparison: Sermorelin vs CJC-1295 deep comparison.
CJC-1295 acts at the upstream GHRH receptor (GH-Releasing Factors subcategory); Ipamorelin acts at the downstream ghrelin receptor (GHS-R1a, GH-Releasing Peptides subcategory). Both are WADA S2-prohibited — different subcategory labels, identical practical consequence for tested athletes. The two-receptor-pathway model underlying the CJC-1295 + Ipamorelin blend is mechanistically grounded: GHRH-receptor amplification + ghrelin-receptor amplification produce supra-additive acute GH-pulse amplitude. The clinical outcome evidence for the blend in humans remains absent.
Full comparison: Sermorelin vs Ipamorelin deep comparison (receptor-pathway overlap with CJC-1295).
For actual adult GH-deficiency diagnoses, recombinant GH (somatropin) is the FDA-approved therapy with decades of human RCT data. Macimorelin (Macrilen) is the only FDA-approved oral GH secretagogue, used for diagnostic AGHD workup only — not for therapy. Tesamorelin (Egrifta) is the FDA-approved GHRH analog for HIV-associated lipodystrophy — a narrow approved indication in a specific patient population. CJC-1295 sits outside all three pathways as an unapproved research-chemical GHRF whose clinical development was never completed.
Here's the straightforward assessment.
Pharmacokinetically longer than Sermorelin. Not more proven. Same upstream receptor, same evidence gap. Never FDA-approved. WADA S2-prohibited.
CJC-1295 with DAC is a real pharmacokinetic class — the albumin-binding modification that extends the half-life to days is documented science. The GHRH-receptor mechanism is well-characterised at the receptor-pharmacology level. The synergy rationale for pairing CJC-1295 with Ipamorelin is mechanistically coherent for acute GH-pulse amplitude.
The leap from "pharmacokinetically longer GHRH-receptor agonist" to "superior evidence for body composition, anti-aging, or longevity outcomes" is exactly the leap that is not supported. The evidence base for chronic clinical outcomes is identical to Sermorelin — which is to say, absent for adult body composition, anti-aging, sleep quality, or recovery as of August 2026. The DAC modification extended the half-life; it did not generate new clinical trials.
It is not something to use with confidence based on forum testimonials, podcast recommendations, or vendor copy distinguishing it from Sermorelin on pharmacokinetic grounds. The chronic-dose human evidence gap for CJC-1295 is, if anything, deeper than Sermorelin — which at least had a completed FDA-approval and withdrawal process generating some pharmacokinetic and safety characterisation.
If you're considering CJC-1295, the minimum due diligence is: understand the actual evidence base for the outcome you're targeting (likely zero human RCT data, and no CJC-1295-specific chronic PK study), know the WADA S2 implications if you're an athlete (both DAC and non-DAC forms), request a COA from an independent lab with identity, purity (>95%), and endotoxin testing if you proceed, and talk to a physician familiar with GH-axis pharmacology who is not also selling the compound to you.
For a structured framework before any decision, see the Peptide Safety & Evidence Decoder Kit.
The Peptide Safety & Evidence Decoder Kit walks you through the questions a qualified physician would ask — sourcing verification, regulatory status in your jurisdiction, bloodwork baseline, drug interactions, and when to walk away. $27, instant PDF delivery.
Get the Decoder Kit →